Navigation Links
Biosimilars Market Expected to Soar
Date:2/14/2013

LONDON, Feb. 14, 2013 /PRNewswire/ -- Top representatives from the healthcare industry are confirmed to attend the 2nd Biosimilars Congregation which will take place in London on the 19th and 20th of February 2013. Ranjith Gopinathan , Frost & Sullivan Program Manager for Life Sciences, Europe Practice, is set to participate to the event's Keynote Panel Discussion focusing on challenges and opportunities in the global biosimilars market.

"Experience in biosimilars development, manufacturing and commercialisation in regulated markets such as Europe and the US is limited. Furthermore, reluctance from some physicians and patients to adopt biosimilars due to perceived efficacy and safety issues could have an adverse impact on market penetration. Such uncertainties, in addition to the complex regulatory pathway, compound the risks for biosimilars manufacturers," says Ranjith Gopinathan , Frost & Sullivan Program Manager for Life Sciences, Frost & Sullivan.

Initially, manufacturers of biosimilars will focus on the 3 protein classes of erythropoiein and human growth hormone due to their recent patent expiry. In the long run, insulin, interferon and more complex proteins like monoclonal antibodies are likely to emerge.  However, some companies may concentrate on certain therapeutic classes depending on their capabilities and strategic fit.

Europe has the highest number of biosimilars approvals in the regulated market and will continue to increase in the near future. Further patent expiries of biologics will likely increase the number of approved biosimilars and players in the market and thereby will bring in a greater number of products that will increase the market size. Biosimilars are currently priced at about 20-30% bel
'/>"/>

SOURCE Frost & Sullivan
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. FDA New Guidelines for Biosimilars and Biobetters: An Outlook for 2013
2. UBM Conferences Unveils Details for Upcoming Generics and Biosimilars Conference
3. Biosimilars: Global Markets
4. Despite Recession, Global Biosimilars Market Grew Over 40% 2010-2011, Set to Reach $3.6 Billion by 2016
5. Immune Deficiency Foundation Urges FDA To Exempt Immunoglobulin From Biosimilars Pathway
6. Nektar to Announce Financial Results for the Fourth Quarter and Year-End of 2012 On Thursday, February 28, 2013, After Close of U.S.-Based Financial Markets
7. Intraocular Lens (IOL) Market Worth $3.8 Billion By 2018 Say New Research Report at ReportsnReports.com
8. New Product Launch: Are your Strategies for Emerging Healthcare and Life Sciences Markets Innovative and Structured?
9. Regenerative Medicine and Stem Cells Market Deals Analysis in New Research Report at ReportsnReports.com
10. Plunketts Biotech & Genetics Industry Almanac 2013: Biotech & Genetics Industry Market Research, Statistics, Trends & Leading Companies
11. Cellular Therapy Market and Cord Blood Market 2013 Industry Research Report: MarketResearchReports.Biz
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... TORONTO , May 21, 2015 /PRNewswire/ - SQI ... SQIDF),a life sciences company that develops and commercializes proprietary ... its financial and operational results for the second fiscal ... the quarter the Company continued to advance business with ... Andrew Morris , President and CEO of SQI. ...
(Date:5/21/2015)... 2015 Specialty Pharmacy Times has ... admitted to BPA Worldwide as a business publication ... audience data for Specialty Pharmacy Times based on ... becoming a member of BPA Worldwide, Specialty Pharmacy ... clients with the most reliable, unequaled data,” said ...
(Date:5/21/2015)...  Prima Biomed Ltd. (NASDAQ: PBMD ) a ... a leader in the development of immunotherapeutic products for ... CVac data from the Phase II CAN-003 ovarian cancer ... clinically meaningful improvement in Overall Survival ("OS") over standard ... In the group of second remission patients (n=20), the ...
(Date:5/21/2015)...  The EveryLife Foundation for Rare Diseases applauded ... Amy Klobuchar (D-MN) today for introducing the ... or OPEN ACT. Supported by more ... bipartisan legislation promises to rapidly bring hundreds of ... patients by incentivizing drug makers to "repurpose" approved ...
Breaking Biology Technology:SQI Diagnostics Reports Second Quarter Financial Results 2SQI Diagnostics Reports Second Quarter Financial Results 3SQI Diagnostics Reports Second Quarter Financial Results 4SQI Diagnostics Reports Second Quarter Financial Results 5SQI Diagnostics Reports Second Quarter Financial Results 6SQI Diagnostics Reports Second Quarter Financial Results 7SQI Diagnostics Reports Second Quarter Financial Results 8Specialty Pharmacy Times Joins BPA Worldwide 2Correction Continues after Big Move - BrokerBank Securities, Inc. 2Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2
... Toronto Stock Exchange Symbol: LRILAVAL, QC, Feb. 9 /PRNewswire-FirstCall/ ... "Company") (TSX: LRI), a Canadian-based global non-clinical contract research ... Spalding as Chairman of its Board of Directors in ... wish to step down of the Board to focus ...
... and PARIS, February 9 Debiopharm,Group (Debiopharm), ... serious medical conditions and particularly oncology, and,Pharmaleads ... early development,company, today announced the signature of ... and commercialisation of a small molecule,called Debio ...
... 3SBio Inc.,(Nasdaq: SSRX ), a leading ... biopharmaceutical products primarily,in China, today announced that it ... effective February 1, 2009. Since joining 3SBio in ... financial advisor for the company, providing advice,on the ...
Cached Biology Technology:LAB Research announces changes to its Board of Directors 2Debiopharm and Pharmaleads Sign License Agreement for Debio 0827 or PL37 in Treatment of Chronic Pain Conditions 2Debiopharm and Pharmaleads Sign License Agreement for Debio 0827 or PL37 in Treatment of Chronic Pain Conditions 33SBio Inc. Appoints Mr. Bo Tan as Chief Financial Officer 2
(Date:5/14/2015)... YORK , May 14, 2015 /PRNewswire/ ... in identity verification and online remote proctoring, ... a software-as-a-service (SaaS) company and creator of ... customers of the two companies will benefit ... in Canvas. As a fully ...
(Date:5/8/2015)... May 8, 2015 Synaptics Inc. (NASDAQ: SYNA ... that members of the executive management team will present at ... Technology, Media and Telecom Conference Date: May 18, 2015 ... Boston, MA Cowen and Company ... 2:45pm ET Location: The New York Palace Hotel, ...
(Date:4/27/2015)... Apr. 27, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, announces ... pre-order customers the first week of May, 2015 and ... of May. Gino Pereira , ... for the company as Wocket® enters the consumer market. ...
Breaking Biology News(10 mins):Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Synaptics to Present at Upcoming Investor Conferences 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3
... Covalys Biosciences AG today announced a collaboration to ... generate SNAP-tag fusion proteins based on Gene Bridges' ... does not require restriction enzymes and allows the ... (bacterial artificial chromosomes) with single-nucleotide precision. SNAP-tag is ...
... Like humans, other animals are faced with everyday obstacles ... and motor skills to deal with them. Navigating these ... other vertebrates, but in new work, researchers have employed ... structure of goal-oriented motor programs in the fruit fly ...
... help stem the global HIV epidemic is to give ... drug tenofovir) before they have high risk sex in ... an approach called "pre-exposure prophylaxis" (PREP). But activist groups, ... least two important clinical trials of tenofovir as PREP ...
Cached Biology News:Gene Bridges And Covalys To Develop Restriction-Enzyme-Free SNAP-tag Gene Fusion Kits 2Gap-climbing fruit flies reveal components of goal-driven behaviors 2Why were the HIV prevention trials in commercial sex workers abandoned? 2
96 Well Plate EB, RE bottom; high binding irradiated surface to provide increased binding affinity for hydrophilic proteins and complexes. Guaranteed coefficient of variation (CVs)....
The Holten mini vertical flow workbench provides a particle-free environment for sample protection against airborne contaminants....
...
Medium bottle for hybridization 250 x 35mm...
Biology Products: